Article Information
History
- September 23, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Josephine Q.N. Nguyen, MD1,2,
- Wojtek Drabarek, MD3,
- Jolanda Vaarwater, BS1,2,
- Serdar Yavuzyigitoglu, MD, PhD1,
- Robert M. Verdijk, MD, PhD4,5,
- Dion Paridaens, MD, PhD1,3,
- Nicole C. Naus, MD, PhD1,
- Annelies de Klein, PhD2,
- Erwin Brosens, PhD2,7,*,
- Emine Kiliç, MD, PhD1,7,* and
- the Rotterdam Ocular Melanoma Study group
- 1Department of Ophthalmology, Erasmus MC Cancer Institute, Erasmus MC Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands
- 2Department of Clinical Genetics, Erasmus MC Cancer Institute, Erasmus MC Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands
- 3The Rotterdam Eye Hospital, 3011 BH, Rotterdam, The Netherlands
- 4Department of Pathology, Section Ophthalmic Pathology, Erasmus MC Cancer Institute, Erasmus MC Medical Center Rotterdam, 3000 CA Rotterdam, The Netherlands
- 5Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands
- ↵*Correspondence: e.brosens{at}erasmusmc.nl, e.kilic{at}erasmusmc.nl
↵7 These authors contributed equally to this work.
Posted September 23, 2022.
Prognostic value of 8q gain in relation to BAP1 and SF3B1 mutated uveal melanoma
